Cellectis S.A. - Ordinary Shares, nominal value EUR0.05 per share (CLLS)

Historical Holders from Q1 2015 to Q3 2025

Symbol
CLLS on Nasdaq
Type / Class
Equity / Ordinary Shares, nominal value EUR0.05 per share
Shares outstanding
95,490,450
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
8,311,195
Holdings value
$23,687,285
% of all portfolios
0.001%
Number of holders
28
Number of buys
13
Number of sells
-9
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Cellectis S.A. - Ordinary Shares, nominal value EUR0.05 per share (CLLS)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ASTRAZENECA PLC 44% $66,440,000 44,000,000 AstraZeneca PLC 23 Jan 2025
Bpifrance Participations SA 11.1% -15.4% $33,176,247 +$960,243 10,599,440 +3% Caisse des Depots 03 Dec 2025
Long Focus Capital Management, LLC 4.6% $6,972,112 4,617,293 LONG FOCUS CAPITAL MANAGEMENT, LLC 31 Dec 2024

Institutional Holders of Cellectis S.A. - Ordinary Shares, nominal value EUR0.05 per share (CLLS)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 8,311,195 $23,687,285 -$5,592,819 $2.85 28
2025 Q2 11,757,728 $17,853,958 -$2,754,141 $1.52 24
2025 Q1 13,602,212 $16,864,343 -$51,496 $1.24 27
2024 Q4 12,759,251 $22,964,294 -$366,691 $1.8 29
2024 Q3 9,766,379 $20,863,531 -$17,239 $2.14 27
2024 Q2 9,772,625 $18,275,141 +$2,408,132 $1.87 27
2024 Q1 9,854,602 $26,115,627 +$90,284 $2.65 31
2023 Q4 9,816,725 $30,235,236 -$3,425,688 $3.08 33
2023 Q3 11,480,546 $18,138,183 -$4,873,642 $1.58 28
2023 Q2 14,008,673 $27,590,926 -$2,313,872 $1.97 31
2023 Q1 15,157,594 $29,256,650 +$12,430,028 $1.93 29
2022 Q4 8,733,333 $18,344,069 -$3,514,674 $2.1 37
2022 Q3 10,299,547 $23,616,856 -$1,469,623 $2.29 43
2022 Q2 10,831,048 $30,655,602 -$4,582,029 $2.83 39
2022 Q1 12,267,940 $55,746,674 -$33,254,202 $4.54 45
2021 Q4 15,187,964 $123,726,723 -$17,963,859 $8.12 55
2021 Q3 15,388,771 $194,068,172 -$11,531,807 $12.61 65
2021 Q2 16,213,399 $250,623,262 +$15,081,703 $15.47 71
2021 Q1 15,242,452 $308,003,839 -$24,336,115 $20.21 78
2020 Q4 16,303,634 $441,619,228 +$62,320,026 $27.06 83
2020 Q3 14,221,535 $263,393,288 +$6,612,668 $18.5 70
2020 Q2 13,884,259 $246,854,298 -$7,256,587 $17.8 77
2020 Q1 14,368,296 $132,185,088 +$10,383,968 $9.2 60
2019 Q4 13,222,126 $226,376,965 +$2,249,267 $17.12 56
2019 Q3 13,148,118 $136,738,200 -$8,890,725 $10.4 60
2019 Q2 13,435,563 $209,551,644 +$8,545,734 $15.6 66
2019 Q1 12,740,024 $233,652,737 +$24,305,612 $18.34 61
2018 Q4 11,487,097 $191,259,158 -$7,897,776 $16.65 62
2018 Q3 11,517,705 $325,035,828 +$5,780,905 $28.22 78
2018 Q2 11,275,435 $319,022,621 +$114,519,929 $28.29 82
2018 Q1 7,051,580 $222,126,151 -$5,958,926 $31.51 67
2017 Q4 7,308,253 $213,043,133 +$42,490,371 $29.15 55
2017 Q3 5,872,301 $167,046,670 +$17,699,694 $28.45 41
2017 Q2 5,258,779 $135,752,000 -$10,905,829 $25.82 39
2017 Q1 5,703,192 $136,879,000 +$1,857,397 $24 39
2016 Q4 5,670,274 $96,110,000 -$23,068,115 $16.95 36
2016 Q3 6,638,753 $159,861,000 -$772,505 $24.08 38
2016 Q2 6,932,847 $184,344,000 +$12,602,577 $26.59 38
2016 Q1 6,465,692 $177,790,378 -$18,348,502 $27.5 43
2015 Q4 7,051,276 $218,793,000 +$7,781,538 $31.03 47
2015 Q3 6,877,612 $181,305,000 +$7,208,463 $26.36 43
2015 Q2 6,601,328 $238,170,032 +$18,429,242 $36.08 40
2015 Q1 6,124,463 $211,832,000 +$211,832,000 $34.59 44